"We have chosen the moment of a repurchase as first clinical...

"We have chosen the moment of a repurchase as first clinical results for 2024 are published, and we will
keep at it until those who gamble against the Company have understood the message. Given the
expected future cash flows, we are in the position to prolong the program when required"

My interpretation of 'keeping at it' must be a bit different. Since the buyback was announced those who gamble against the company have increased their open short positions by close to 1% (500000 fake liquidity shares sold) and put Clinuvel into the top 20 most shorted stocks. They are controlling the share price and the narrative and Clinuvel are seemingly content with this, and also content to withhold info on the Vitiligo trial ,which lucky for us a Dermatologist at a major US conference showed again how effective the CUV drug is for treating that disease.

Since the great news of the buyback was announced on 14/03 we have also had a really positive newsletter with the above quote, and also from a potential competitor in Disc we have had great news they flunked their EPP phase 2 which means the Clinuvel EPP monopoly will continue for many years to come. In response to three great pieces of news in one month, those who gamble against the company have used enormous amounts of fake liquidity to control the share price. IMO it would have probably returned to mid $20s if the shorters had not stepped up their manipulation efforts to control the price via introduced Sell liquidity (mid $20s is where most analyst PTs are just on EPP). Yet the share buyback bought a couple of shares and stopped, it should have done the opposite and actually sent the message the above quote talks about. That is, buy some big chunks of shares over several days and remove 200 - 300 thousand shares really quickly and then still have over one million shares in hand to grind away against the daily manipulation that shorters are once again doing. If they want to accumulate as many low cost shares as possible at the shorters expense then why have they stopped after only 3 days of buying back? They have lost momentum and given the initiative back to the shorters by stopping so early - or not really starting for that matter.

Those who gamble against the company may not have understood the message just yet but the gamble they are taking on is huge (unless it's for a cheap takeover). The drug for blockbuster Vitiligo is already FDA, TGA, EMA approved and with great Safety so they have already lost that part of the bet. Does it work for Vitiligo? All indications would seem to point to excellent efficacy and betting against efficacy would seem to be a high risk endeavour IMO. A good chance it will become the standard of care if approved and Clinuvel have stated they want to have 120 US centres ready to go upon approval (50 - 70 already sorted I believe). CUV also stated $490 - $570 Million USD penetration in years 1-2 I believe (most of this info comes from the Sydney Vitiligo presentation released on 10/11/23) and a lot of this will simply drop to the bottom line as CUV is already very profitable. FDA submission 2026 in just two years and the approval process easier since it is just a new indication, not a new drug application. Only 50 million shares on issue (and 48.5M after the buyback) to share profits amongst. Blockbuster Stroke and everything else not priced in at all. Just reaffirm Vitiligo is on track, consistently use the buyback to buy shares, and I will also buy more shares and help out the share buyback (the Directors could help a bit too). Clinuvel need to just keep at it until it is clear those who gamble against the company have understood the message.

All IMO DYOR